AstraZeneca Signs Licensing Deal for Starpharma Drug-Delivery Technology
AstraZeneca Signs Licensing Deal for Starpharma Drug-Delivery
Technology
AstraZeneca signed a licensing deal with
Australian firm Starpharma to use Starpharma's DEP dendrimer conjugate
drug-delivery platform in the development and commercialization of one of
AstraZeneca's oncology candidates. Starpharma says that its technology can
yield improved solubility, less off-target toxicity, and improved efficacy.
Starpharma is guaranteed $2 million for the oncology candidate, which also
includes development milestone payments up to $64 million and sales milestones
of up to $60 million. Use of Starpharma's platform with subsequent AstraZeneca
drug candidates could net the Australian firm milestone payments of up to $53.3
million and sales milestones of up to $40 million per drug, as well as tiered
royalties on net sales. Starpharma CEO Jackie Fairley says successful
commercialization could bring Starpharma as much as $450 million per drug.
From "AstraZeneca Signs Drug Delivery
Licensing Deal with Starpharma Potentially Worth $126M+". FierceDrugDelivery
(09/11/2015) Saxena, Varun
Link: AstraZeneca Signs Licensing Deal for Starpharma
Drug-Delivery Technology